Pharmacogenomics  ||| S:0 E:17 ||| NNP
of  ||| S:17 E:20 ||| IN
taxane ||| S:20 E:26 ||| CD
/ ||| S:26 E:27 ||| CD
platinum  ||| S:27 E:36 ||| NN
therapy  ||| S:36 E:44 ||| NN
in  ||| S:44 E:47 ||| IN
ovarian  ||| S:47 E:55 ||| JJ
cancer  ||| S:55 E:62 ||| NN
Taxane  ||| S:62 E:69 ||| NNP
( ||| S:69 E:70 ||| -LRB-
paclitaxel  ||| S:70 E:81 ||| NN
or  ||| S:81 E:84 ||| CC
docetaxel ||| S:84 E:93 ||| CD
)  ||| S:93 E:95 ||| -RRB-
and  ||| S:95 E:99 ||| CC
platinum  ||| S:99 E:108 ||| NN
( ||| S:108 E:109 ||| -LRB-
cisplatin  ||| S:109 E:119 ||| NN
or  ||| S:119 E:122 ||| CC
carboplatin ||| S:122 E:133 ||| CD
)  ||| S:133 E:135 ||| -RRB-
chemotherapy  ||| S:135 E:148 ||| NN
is  ||| S:148 E:151 ||| VBZ
commonly  ||| S:151 E:160 ||| RB
used  ||| S:160 E:165 ||| VBN
in  ||| S:165 E:168 ||| IN
the  ||| S:168 E:172 ||| DT
treatment  ||| S:172 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
ovarian  ||| S:185 E:193 ||| JJ
cancer ||| S:193 E:199 ||| NN
.  ||| S:199 E:201 ||| .
Despite  ||| S:201 E:209 ||| IN
an  ||| S:209 E:212 ||| DT
initial  ||| S:212 E:220 ||| JJ
high  ||| S:220 E:225 ||| JJ
response  ||| S:225 E:234 ||| NN
to  ||| S:234 E:237 ||| TO
therapy ||| S:237 E:244 ||| NN
,  ||| S:244 E:246 ||| ,
the  ||| S:246 E:250 ||| DT
5-year  ||| S:250 E:257 ||| JJ
survival  ||| S:257 E:266 ||| NN
rate  ||| S:266 E:271 ||| NN
remains  ||| S:271 E:279 ||| VBZ
low ||| S:279 E:282 ||| JJ
.  ||| S:282 E:284 ||| .
The  ||| S:284 E:288 ||| DT
identification  ||| S:288 E:303 ||| NN
of  ||| S:303 E:306 ||| IN
pharmacogenomic  ||| S:306 E:322 ||| JJ
markers  ||| S:322 E:330 ||| NN
to  ||| S:330 E:333 ||| TO
identify  ||| S:333 E:342 ||| VB
patients  ||| S:342 E:351 ||| NNS
unlikely  ||| S:351 E:360 ||| JJ
to  ||| S:360 E:363 ||| TO
respond  ||| S:363 E:371 ||| VB
or  ||| S:371 E:374 ||| CC
at  ||| S:374 E:377 ||| IN
risk  ||| S:377 E:382 ||| NN
for  ||| S:382 E:386 ||| IN
severe  ||| S:386 E:393 ||| JJ
toxicity  ||| S:393 E:402 ||| NN
will  ||| S:402 E:407 ||| MD
assist  ||| S:407 E:414 ||| VB
in  ||| S:414 E:417 ||| IN
the  ||| S:417 E:421 ||| DT
goal  ||| S:421 E:426 ||| NN
of  ||| S:426 E:429 ||| IN
individualizing  ||| S:429 E:445 ||| JJ
ovarian  ||| S:445 E:453 ||| JJ
cancer  ||| S:453 E:460 ||| NN
treatment ||| S:460 E:469 ||| NN
.  ||| S:469 E:471 ||| .
Most  ||| S:471 E:476 ||| JJS
studies  ||| S:476 E:484 ||| NNS
have  ||| S:484 E:489 ||| VBP
assessed  ||| S:489 E:498 ||| VBN
single  ||| S:498 E:505 ||| JJ
nucleotide  ||| S:505 E:516 ||| JJ
polymorphisms  ||| S:516 E:530 ||| NN
from  ||| S:530 E:535 ||| IN
genes  ||| S:535 E:541 ||| NNS
involved  ||| S:541 E:550 ||| VBN
in  ||| S:550 E:553 ||| IN
the  ||| S:553 E:557 ||| DT
pharmacokinetics  ||| S:557 E:574 ||| NN
and  ||| S:574 E:578 ||| CC
pharmacodynamics  ||| S:578 E:595 ||| NN
of  ||| S:595 E:598 ||| IN
the  ||| S:598 E:602 ||| DT
drugs ||| S:602 E:607 ||| NNS
.  ||| S:607 E:609 ||| .
Unfortunately ||| S:609 E:622 ||| RB
,  ||| S:622 E:624 ||| ,
most  ||| S:624 E:629 ||| RBS
markers  ||| S:629 E:637 ||| JJ
identified  ||| S:637 E:648 ||| NNS
have  ||| S:648 E:653 ||| VBP
not  ||| S:653 E:657 ||| RB
been  ||| S:657 E:662 ||| VBN
replicated  ||| S:662 E:673 ||| VBN
in  ||| S:673 E:676 ||| IN
subsequent  ||| S:676 E:687 ||| JJ
studies ||| S:687 E:694 ||| NNS
.  ||| S:694 E:696 ||| .
Other  ||| S:696 E:702 ||| JJ
mechanisms  ||| S:702 E:713 ||| NNS
of  ||| S:713 E:716 ||| IN
variability ||| S:716 E:727 ||| NN
,  ||| S:727 E:729 ||| ,
including  ||| S:729 E:739 ||| VBG
epigenetic  ||| S:739 E:750 ||| JJ
control  ||| S:750 E:758 ||| NN
of  ||| S:758 E:761 ||| IN
gene  ||| S:761 E:766 ||| NN
expression  ||| S:766 E:777 ||| NN
and  ||| S:777 E:781 ||| CC
copy  ||| S:781 E:786 ||| NN
number  ||| S:786 E:793 ||| NN
variation ||| S:793 E:802 ||| NN
,  ||| S:802 E:804 ||| ,
may  ||| S:804 E:808 ||| MD
play  ||| S:808 E:813 ||| VB
important  ||| S:813 E:823 ||| JJ
roles ||| S:823 E:828 ||| NNS
.  ||| S:828 E:830 ||| .
In  ||| S:830 E:833 ||| IN
addition ||| S:833 E:841 ||| NN
,  ||| S:841 E:843 ||| ,
nongenetic  ||| S:843 E:854 ||| NN
influences  ||| S:854 E:865 ||| VBZ
such  ||| S:865 E:870 ||| JJ
as  ||| S:870 E:873 ||| IN
concurrent  ||| S:873 E:884 ||| JJ
medications ||| S:884 E:895 ||| NN
,  ||| S:895 E:897 ||| ,
and  ||| S:897 E:901 ||| CC
physiological  ||| S:901 E:915 ||| NNS
and  ||| S:915 E:919 ||| CC
environmental  ||| S:919 E:933 ||| JJ
factors  ||| S:933 E:941 ||| NNS
could  ||| S:941 E:947 ||| MD
also  ||| S:947 E:952 ||| RB
affect  ||| S:952 E:959 ||| VB
individual  ||| S:959 E:970 ||| JJ
responses  ||| S:970 E:980 ||| NNS
to  ||| S:980 E:983 ||| TO
taxane  ||| S:983 E:990 ||| VB
and  ||| S:990 E:994 ||| CC
platinum  ||| S:994 E:1003 ||| NN
therapy ||| S:1003 E:1010 ||| NN
.  ||| S:1010 E:1012 ||| .
